Protecting the endometrium: Opposing the hyperplasia/malignancy potential of ERT

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 44, Issue 2 SUPPL., 1999, Pages 203-208

  Gibbons, William E ^a   Thorneycroft, Ian H ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Endometrial hyperplasia; Endometrial neoplasms; Endometrium; Estrogen replacement therapy

Indexed keywords

ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

CANCER RISK; CONFERENCE PAPER; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HUMAN; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PROGESTERONE; PROGESTERONE CONGENERS; RISK FACTORS;

EID: 0032969970     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Grady D, Gebretsadik T, Kerlikowske K, et al: Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304-313
2. Gordon J, Reagan JW, Finkle WD, et al: Estrogen and endometrial carcinoma: An independent pathology review supporting original risk estimate. N Engl J Med 1977;297: 570-511
3. The Writing Group for the PEPI Trial: Effects of hormonal replacement therapy on endometrial histology in postmenopausal women. JAMA 1996;275:370-375
4. Gelfand MM, Ferenczy A: A prospective 1-year study of estrogen and progestin postmenopausal women: Effects on the endometrium. Obstet Gynecol 1989;74:398-402
5. Paterson MEL, Wade-Evans T, Sturdee DW, et al: Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J 1980;280:822-824
6. Kurman RJ, Kaminski PF, Norris HJ: The behavior of endometrial hyperplasia: A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-412
7. Woodruff JD, Pickar JH: Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone: The Menopause Study Group. Am J Obstet Gynecol 1994;170:1213-1223
8. Gibbons WE, Moyer DL, Lobo RA, et al: Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol 1986;154:456-461
9. Gibbons WE, Judd HL, Moyer D, et al: Evaluation of sequential versus continuous estrogen/progestin replacement therapy in uterine bleeding patterns and endometrial histology. Presented at the 38th annual meeting of the Society of Gynecologic Investigation, San Antonio, March 20-23, 1991
10. Archer DF, Cuffie CA, Lobo RA, et al: The endometrial histologic effects of oral micronized progesterone in estrogen-treated postmenopausal women (unpublished study)
11. Pickar JH, Archer DF, for the Menopause Study Group: Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy? Am J Obstet Gynecol 1997;177:1178-1183
12. Scurry J, Brand A, Sheehan P, et al: High-grade endometrial carcinoma in secretory endometrium in young women: A report of five cases. Gynecol Oncol 1996;60:224-227
13. Luciano AA, DeSouza MJ, Schoenfeld MJ, et al: Effects of Ogen/Provera on vasomotor symptoms, bleeding patterns and endometrial histology in menopausal women. Presented at the 1998 meeting of the North American Menopause Society, Toronto, Ontario, Canada, September 9-11, 1998
14. Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647